Vidac Pharma Holding (STU:T9G) Enterprise Value : €35.03 Mil (As of Mar. 04, 2025)

Vidac Pharma Holding Enterprise Value Chart

Competitive Comparison of Vidac Pharma Holding's Enterprise Value

For the Biotechnology subindustry, Vidac Pharma Holding's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vidac Pharma Holding's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Vidac Pharma Holding's Enterprise Value falls into.

Vidac Pharma Holding Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Vidac Pharma Holding's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Vidac Pharma Holding's Enterprise Value for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding  (STU:T9G) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Vidac Pharma Holding's EV-to-EBIT for today is

Vidac Pharma Holding's current Enterprise Value is €35.03 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vidac Pharma Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.37 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Vidac Pharma Holding's EV-to-EBITDA for today is:

Vidac Pharma Holding's current Enterprise Value is €35.03 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vidac Pharma Holding's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.37 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Vidac Pharma Holding's EV-to-Revenue for today is:

Vidac Pharma Holding's current Enterprise Value is €35.03 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vidac Pharma Holding's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Vidac Pharma Holding's EV-to-FCF for today is:

Vidac Pharma Holding's current Enterprise Value is €35.03 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vidac Pharma Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding Enterprise Value Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Vidac Pharma Holding Business Description